Amphastar Pharmaceuticals (AMPH) Enterprise Value (2013 - 2026)

Amphastar Pharmaceuticals' Enterprise Value history runs 14 years deep, the most recent figure standing at -$173.1 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 5.38% year-over-year to -$173.1 million; the TTM figure through Mar 2026 stood at -$173.1 million (up 5.38% YoY), while the FY2025 annual figure was -$172.4 million, up 22.23% from the prior year.
• Enterprise Value was -$173.1 million for Q1 2026 at Amphastar Pharmaceuticals, roughly flat from -$172.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$144.5 million in Q4 2023 to a low of -$299.9 million in Q3 2023.
• Historically, Enterprise Value has averaged -$201.0 million across 5 years, with a median of -$184.1 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value plunged 231.58% in 2022, then soared 36.81% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$156.3 million in 2022, then advanced by 7.55% to -$144.5 million in 2023, then tumbled by 53.39% to -$221.6 million in 2024, then gained by 22.23% to -$172.4 million in 2025, then decreased by 0.44% to -$173.1 million in 2026.
• The last three Enterprise Value figures came in at -$173.1 million (Q1 2026), -$172.4 million (Q4 2025), and -$276.2 million (Q3 2025), per Business Quant data.